| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6090410 | ORGANON | Dry mix formulation for bisphosphonic acids |
Dec, 2012
(11 years ago) | |
| US6194004 | ORGANON | Dry mix formulation for bisphosphonic acids |
Dec, 2012
(11 years ago) | |
| US5681590 | ORGANON | Dry mix formulation for bisphosphonic acids |
Dec, 2012
(11 years ago) | |
| US5358941 | ORGANON | Dry mix formulation for bisphosphonic acids with lactose |
Dec, 2012
(11 years ago) | |
|
US5681590 (Pediatric) | ORGANON | Dry mix formulation for bisphosphonic acids |
Jun, 2013
(10 years ago) | |
|
US6090410 (Pediatric) | ORGANON | Dry mix formulation for bisphosphonic acids |
Jun, 2013
(10 years ago) | |
|
US5358941 (Pediatric) | ORGANON | Dry mix formulation for bisphosphonic acids with lactose |
Jun, 2013
(10 years ago) | |
|
US6194004 (Pediatric) | ORGANON | Dry mix formulation for bisphosphonic acids |
Jun, 2013
(10 years ago) | |
Fosamax is owned by Organon.
Fosamax contains Alendronate Sodium.
Fosamax has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Fosamax are:
- US6090410
- US6194004
- US5681590
- US5358941
- US5681590*PED
- US6090410*PED
- US5358941*PED
- US6194004*PED
Fosamax was authorised for market use on 25 April, 1997.
Fosamax is available in tablet;oral dosage forms.
The generics of Fosamax are possible to be released after 02 June, 2013.
Drugs and Companies using ALENDRONATE SODIUM ingredient
Market Authorisation Date: 25 April, 1997
Treatment: NA
Dosage: TABLET;ORAL
FOSAMAX family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5462932 | MERCK | Oral liquid alendronate formulations |
May, 2014
(9 years ago) | |
|
US5462932 (Pediatric) | MERCK | Oral liquid alendronate formulations |
Nov, 2014
(9 years ago) | |
| US6225294 | MERCK | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US6015801 | MERCK | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US5994329 | MERCK | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
|
US5994329 (Pediatric) | MERCK | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US6225294 (Pediatric) | MERCK | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US6015801 (Pediatric) | MERCK | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
Fosamax is owned by Merck.
Fosamax contains Alendronate Sodium.
Fosamax has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Fosamax are:
- US5462932
- US5462932*PED
- US6225294
- US6015801
- US5994329
- US5994329*PED
- US6225294*PED
- US6015801*PED
Fosamax was authorised for market use on 17 September, 2003.
Fosamax is available in solution;oral dosage forms.
The generics of Fosamax are possible to be released after 17 January, 2019.
Drugs and Companies using ALENDRONATE SODIUM ingredient
Market Authorisation Date: 17 September, 2003
Treatment: NA
Dosage: SOLUTION;ORAL
FOSAMAX family patents